Shinichi Toyooka

Medicine & Life Sciences

1. Adenocarcinoma 6%
2. Adenocarcinoma of Lung 24%
3. Adjuvant Chemotherapy 7%
4. Afatinib 7%
5. Allografts 6%
6. Breast Neoplasms 14%
7. Cell Line 22%
8. Chemoradiotherapy 30%
9. Cisplatin 9%
10. Databases 6%
11. DNA Methylation 7%
12. Docetaxel 10%
13. Drug Therapy 6%
14. Epigenomics 7%
15. ErbB Receptors 41%
16. erbB-1 Genes 22%
17. Exons 7%
18. Gefitinib 24%
19. Genes 15%
20. human DAB2 protein 6%
21. human ERBB2 protein 13%
22. Japan 11%
23. Living Donors 27%
24. Lung 50%
25. Lung Neoplasms 76%
26. Lung Transplantation 57%
27. Lymph Nodes 6%
28. Malignant Mesothelioma 22%
29. Methylation 39%
30. MicroRNAs 7%
31. Mutation 32%
32. Needle Biopsy 5%
33. Neoplasm Metastasis 14%
34. Neoplasms 35%
35. Non-Small Cell Lung Carcinoma 100%
36. Polymerase Chain Reaction 9%
37. Protein-Tyrosine Kinases 13%
38. Radiofrequency Ablation 21%
39. Recurrence 8%
40. Small Cell Lung Carcinoma 8%
41. Smokers 8%
42. Smoking 6%
43. Survival 21%
44. Survival Rate 8%
45. Therapeutics 13%
46. Thorax 8%
47. Tissue Donors 7%
48. Tomography 10%
49. Transplants 11%
50. Tumor Suppressor Genes 7%